New Targets in Non–Small Cell Lung Cancer

Publication date: February 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 1
Author(s): Soo J. Park, Soham More, Ayesha Murtuza, Brian D. Woodward, Hatim Husain

Teaser

With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non–small cell lung cancer. The clinical success of tyrosine kinase inhibitors against epidermal growth factor receptor and anaplastic lymphoma kinase activation has shifted treatment emphasize the separation of subsets of lung cancer and genotype-directed therapy. Advances have validated oncogenic driver genes and led to the development of targeted agents. This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations.


http://ift.tt/2gK3DqK